|
1
|
International Agency for Research on
Cancer, . Colorectal cancer estimated incidence, mortality and
prevalence worldwide in 2012 [EB/OL]. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
|
|
2
|
Zong-Guang Zhou, Lie Yang, Yuan Li, et al:
The 30 years' changes of colorectal cancer and the strategies in
China. Chin J Practic Surg. 32:693–696. 2012.(In Chinese).
|
|
3
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wieck MM, Spurrier RG, Levin DE, Mojica
SG, Hiatt MJ, Reddy R, Hou X, Navarro S, Lee J, Lundin A, et al:
Sequestration of vascular endothelial growth factor (VEGF) induces
late restrictive lung disease. PLoS One. 11:e01483232016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin LJ, Zheng CQ, Jin Y, Ma Y, Jiang WG
and Ma T: Expression of survivin protein in human colorectal
carcinogenesis. World J Gastroenterol. 9:974–977. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Willems-Widyastuti A, Vanaudenaerde BM,
Vos R, Dilisen E, Verleden SE, De Vleeschauwer SI, Vaneylen A, Mooi
WJ, de Boer WI, Sharma HS and Verleden GM: Azithromycin attenuates
fibroblast growth induced vascular endothelial growth factor via
p38(MAPK)signaling in human airway smooth muscle cells. Cell
Biochem Biophys. 67:331–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zachary I and Gliki G: Signaling
transduction mechanisms mediating biological actions of the
vascular endothelial growth factor family. Cardiov Asc Res.
49:568–581. 2001. View Article : Google Scholar
|
|
8
|
Zeng H, Sanyal S and Mukhopadhyay D:
Tyrosine residues 951 and 1059 of vascular endothelial growth
factor receptor-2 (KDR) are essential for vascular permeability
factor/vascular endothelial growth factor-induced endothelium
migration and proliferation, respectively. Biol Chem.
276:32714–32719. 2001. View Article : Google Scholar
|
|
9
|
Xu XL, Ling ZQ, Chen W, Xu YP and Mao WM:
The overexpression of VEGF in esophageal cancer is associated with
a more advanced TMN stage: A meta-analysis. Cancer Biomark.
13:105–113. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Liu X, Zhang J, Li L and Liu C:
The expression and clinical significance of PI3K, pAkt and VEGF in
colon cancer. Oncol Lett. 4:763–766. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ratcliffe PJ: HIF-l and HIF-2: Working
alone or together in hypoxia? J Clin Invest. 117:862–865. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li W, Xiong ZW, Li HW, Hu HX, Zhang P, Su
H, Huang Y, Zhang HD and Xun FH: Expression of COX-2, VEGF and E
-cad in breast cancer and their clinicopathologic significance.
Chin J Curr Adv Gen Surg. 13:766–771. 2010.(In Chinese).
|
|
13
|
Zhang P, Dong L, Yan K, Long H, Yang TT,
Dong MQ, Zhou Y, Fan QY and Ma BA: CXCR4-mediated osteosarcoma
growth and pulmonary metastasis is promoted by mesenchymal stem
cells through VEGF. Oncol Rep. 30:1753–1761. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu Y, Jin M, Xu H, Shimin Z, He S, Wang L
and Zhang Y: Clinicopathologic significance of HIF-1α, CXCR4, and
VEGF expression in colon cancer. Clin Dev Immunol.
2010:pii:5375312010. View Article : Google Scholar
|
|
15
|
Ahluwalia A and Tarnawski AS: Critical
role of hypoxia sensor-HIF-1α in VEGF gene activation. Implications
for angiogenesis and tissue injury healing. Curr Med Chem.
19:90–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De Francesco EM, Lappano R, Santolla MF,
Marsico S, Caruso A and Maggiolini M: HIF-1α/GPER signaling
mediates the expression of VEGF induced by hypoxia in breast
cancer-associated fibroblasts (CAFs). Breast Cancer Res.
15:R642013. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Decourt B, Drumm-Gurnee D, Wilson J,
Jacobson S, Belden C, Sirrel S, Ahmadi M, Shill H, Powell J, Walker
A, et al: Poor safety and Tolerability Hamper Reaching a
potentially therapeutic dose in the use of thalidomide for
Alzheimer's disease: Results from a Double-Blind Placebo-Controlled
trail. Curr Alzheimer Res. 14:403–411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Raturi R, Patel AA and Carter JD: Two
cases demonstrating thalidomide's efficacy in refractory lupus
nephritis. Clin Rheumatol. 36:725–728. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Anargyrou K, Dimopoulos MA, Sezer O and
Terpos E: Novel anti-myeloma agents and angiogenesis. Leuk
Lymphoma. 49:677–689. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bombini G, Canetti C, Rocha FA and Cunha
FQ: Tumour necrosis factor-alpha mediates neutrophil migration to
the knee synovial cavity during immune inflammation. Eur J
Pharmacol. 496:197–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deng L, Ding W and Granstein RD:
Thalidomide inhibits tumor necrosis factor-alpha production and
antigen presentation by Langerhans cells. J Invest Dermatol.
121:1060–1065. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Keifer JA, Guttridge DC, Ashburner BP and
Baldwin AS Jr: Inhibition of NF-kappa B activity by thalidomide
through suppression of IkappaB kinase activity. J Biol Chem.
276:22382–22387. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu J, Liu F, Sun Z, Sun M and Sun S: The
enhancement of radiosensitivity in human esophageal carcinoma cell
by thalidomide and its potential mechanism. Cancer Biother
Radiopharm. 26:219–227. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pan J, Lu GP and Yu ZJ: Thalidomide on
anti-tumor research. Chin J Cancer Prev Treat. 19:552–555.
2012.
|
|
25
|
Uach H, Ritchie D, Stewart AK, Neeson P,
Harrison S, Smyth MJ and Prince HM: Mechanism of action of
immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia.
24:22–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Girgis E, Mahoney J, Darling-Reed S and
Soliman M: Arsenic trioxde enhance the cytotoxic effect of
thalidomide in a KG-la human acute mylogenous leukemia cell line.
Oncol Lett. 1:473–479. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu X, Xiong G, Li E, Zhu H, Lio H, Shen G
and Wu S: Effect of thalidomide on cytodynamics and VEGF expression
of human pancreatic cancer cells. Chin J Gastroenterol. 9:511–513.
2012.
|
|
28
|
Gao S, Yang XJ, Zhang WG, Ji YW and Pan Q:
Mechanism of thalidomide to enhance cytotoxicity of temozolomide in
U251-MG glioma cells in vitro. Chin Med J (Engl). 122:1260–1266.
2009.PubMed/NCBI
|
|
29
|
Lin YC, Shun CT, Wu MS and Chen CC: A
novel anticancer effect of thalidomide: Inhibition of intercellular
adhesion molecule-1-mediated cell invasion and metastasis through
suppression of nuclear factor-kappaB. Clin Cancer Res.
12:7165–7173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
André T, Boni C, Navarro M, Tabernero J,
Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F
and de Gramont A: Improved overall survival with oxaliplatin,
fluorouracil, and leucovorin as adjuvant treatment in stage II or
III colon cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3116.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dahan L, Sadok A, Formento JL, Seitz JF
and Kovacic H: Modulation of cellular redox state underlies
antagonism between oxaliplatin and cetuximab in human colorectal
cancer cell lines. Br J Pharmacol. 158:610–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lv J, Liu N, Liu KW, Ding AP, Wang H and
Qiu WS: A Randomised controlled phase II trial of the combination
of XELOX with thalidomide for the first-line treatment of
metastatic colorectal cancer. Cancer Biol Med. 9:111–114.
2012.PubMed/NCBI
|
|
33
|
Govindarajan R: Irinotecan/thalidomide in
metastatic colorectal cancer. Oncology (Williston park). 16(4 Suppl
3): S23–S26. 2002.
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang MM, Cai L and LA DD: Study on
mechanism of thalidomide in human ovarian cancer cells SKOV3 in
vitro. J Practi Med. 26:2693–2696. 2010.
|
|
37
|
Huang YT, Cheng CC, Chiu TH and Lai PC:
Therapeutic potential of thalidomide for gemcitabine-resistant
bladder cancer. Int J Oncol. 47:1711–1724. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang C and Youle RJ: The role of
mitochondria in apoptosis*. Annu Rev Genet. 43:95–118. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gu W, Zhao XG and Zhang X: Formononetin
induce apoptosis of SKOV3 cells through regulating the expression
of Bax and Bcl-2. Sichuan J Physiol. 36:60–62. 2014.
|
|
40
|
Qiao Z, Yuan J, Shen J, Wang C, He Z, Hu
Y, Zhang M and Xu C: Effect of thalidomide in combination with
gemcitabine on human pancreatic carcinoma SW-1990 cell lines in
vitro and in vivo. Oncol Lett. 9:2353–2360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Marriott JB, Clarke LA, Czajks A, Dredge
K, Childs K, Man HW, Schafer P, Govinda S, Muller GW, Stirling DI
and Dalgleish AG: A novel subclass of thalidomide analogue with
anti-solid tumor activity in which caspase-dependent apoptosis is
associated with altered expression of bcl-2 family proteins. Cancer
Res. 63:593–599. 2003.PubMed/NCBI
|
|
42
|
Meller S and Bhandari V: VEGF levels in
humans and animal models with RDS and BPD: Temporal relationships.
Exp Lung Res. 38:192–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gerber HP, Vu TH, Ryan AM, Kowalski J,
Werb Z and Ferrara N: VEGF couples hypertrophic cartilage
remodeling, ossification and angiogenesis during endochondral bone
formation. Nat Med. 5:623–628. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee CG, Link H, Baluk P, Homer RJ,
Chapoval S, Bhandari V, Kang MJ, Cohn L, Kim YK, McDonald DM and
Elias JA: Vascular endothelial growth factor (VEGF) induces
remodeling and enhances TH2-mediated sensitization and inflammation
in the lung. Nat Med. 10:1095–1103. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhao T, Zhao W, Meng W, Liu C, Chen Y,
Gerling IC, Weber KT, Bhattacharya SK, Kumar R and Sun Y:
VEGF-C/VEGFR-3 pathway promotes myocyte hypertrophy and survival in
the infracted myocardium. Am J Transl Res. 7:697–709.
2015.PubMed/NCBI
|
|
46
|
Iacovelli R, Sternberg CN, Porta C,
Verzoni E, de Braud F, Escudier B and Procopio G: Inhibition of the
VEGF/VEGFR pathway improves survival in advanced kidney cancer: A
systematic review and meta-analysis. Curr Drug Targets. 16:164–170.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Quittet MS, Touzani O, Sindji L, Cayon J,
Fillesoye F, Toutain J, Divoux D, Marteau L, Lecocq M, Roussel S,
et al: Effects of mesenchymal stem cell therapy, in association
with pharmacologically active microcarriers releasing VEGF, in an
ischaemic stroke model in the rat. Acta Biomater. 15:77–88. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dzietko M, Derugin N, Wendland MF, Vexler
ZS and Ferriero DM: Delayed VEGF treatment enhances angiogenesis
and recovery after neonatal focal rodent stroke. Transl Stroke Res.
4:189–200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yang X, Zhu H, Ge Y, Liu J, Cai J, Qin Q,
Zhan L, Zhang C, Xu L, Liu Z, et al: Melittin enhances
radiosensitivity of hypoxic head and neck squamous cell carcinoma
by suppressing HIF-1α. Tumour Biol. 35:10443–10448. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wilkinson-Berka JL: Vasoactive factors and
diabetic retinopathy: Vascular endothelial growth factor,
cycoloxygenase-2 and nitric oxide. Curr Pharm Des. 10:3331–3348.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Buckstein R, Kerbel R, Cheung M, Shaked Y,
Chodirker L, Lee CR, Lenis M, Davidson C, Cussen MA, Reis M, et al:
Lenalidomide and metronomic melphalan for CMML and higher risk MDS:
A phase 2 clinical study with biomarkers of angiogenesis. Leuk Res.
38:756–763. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tan H, Chen H, Xu C, Ge Z, Gao Y, Fang J,
Liu W and Xiao S: Role of vascular endothelial growth factor in
angiodysplasia: An interventional study with thalidomide. J
Gastroenterol Hepatol. 27:1094–1101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hernandez Mde O, Fulco Tde O, Pinheiro RO,
Pereira Rde M, Redner P, Sarno EN, Lopes UG and Sampaio EP:
Thalidomide modulates Mycobacterium leprae-induced NF-κB pathway
and lower cytokine response. Eur J Pharmacol. 670:272–279. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Abcouwer SF: Angiogenic factors and
cytokines in diabetic retinopathy. J Clin Cell Immunol. (Suppl
1)2013.PubMed/NCBI
|
|
55
|
Huang YF, Yang CH, Huang CC, Tai MH and
Hsu KS: Pharmacological and genetic accumulation of
hypoxia-inducible factor-1alpha enhances excitatory synaptic
transmission in hippocampal neurons through the production of
vascular endothelial growth factor. J Neurosci. 30:6080–6093. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Carbajo-Pescador S, Ordonez R, Benet M,
Jover R, García-Palomo A, Mauriz JL and González-Gallego J:
Inhibition of VEGF expression through blockade of Hif1α and STAT3
signaling mediates the anti-angiogenic effect of melatonin in HepG2
liver cancer cells. Br J Cancer. 109:83–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nechemia-Arbely Y, Khamaisi M, Rosenberger
C, Koesters R, Shina A, Geva C, Shriki A, Klaus S, Rosen S,
Rose-John S, et al: In vivo evidence suggesting reciprocal renal
hypoxia-inducible factor-1 upregulation and signal transducer and
activator of transcription 3 activation in response to hypoxic and
non-hypoxic stimuli. Clin Exp Pharmacol Physiol. 40:262–272. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Dourlat J, Liu WQ, Sancier F, Edmonds T,
Pamonsinlapatham P, Cruzalegui F and Garbay C: A novel
non-phosphorylated potential antitumoral peptide inhibits STAT3
biological activity. Biochimie. 91:996–1002. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Majumder S, Sreedhara SR, Banerjee S and
Chatterjee S: TNF-α signaling beholds thalidomide saga: A review of
mechanistic role of TNF-α signaling under thalidomide. Curr Top Med
Chem. 12:1456–1467. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
El-Aarag BY, Kasai T, Zahran MA, Zakhary
NI, Shigehiro T, Sekhar SC, Agwa HS, Mizutani A, Murakami H, Kakuta
H and Seno M: In vitro anti-proliferative and anti-angiogenic
activities of thalidomide dithiocarbamate analogs. Int
Immunopharmacol. 21:283–292. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cook KM and Figg WD: Angiogenesis
inhibitors: Current strategies and future prospects. CA Cancer J
Clin. 60:222–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
People's Republic of China national health
and Family Planning Commission of medical affairs authority, Tumor
branch of Chinese Medical Association, . Standard for diagnosis and
treatment of colorectal cancer (2015). Chin J Practi Surg.
35:1177–1191. 2015.
|
|
63
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Voland C, Bord A, Péleraux A, Pénarier G,
Carrière D, Galiègue S, Cvitkovic E, Jbilo O and Casellas P:
Repression of cell cycle-related proteins by oxaliplatin but not
cisplatin in human colon cancer cells. Mol Cancer Ther.
5:2149–2157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cremolini C, Loupakis F, Masi G, Lonardi
S, Granetto C, Mancini ML, Chiara S, Moretto R, Rossini D, Vitello
S, et al: FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line
treatment of metastatic colorectal cancer: A propensity
score-adjusted analysis from two randomized clinical trials. Ann
Oncol. 27:843–849. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Murphy S, Davey RA, Gu XQ, Haywood MC,
McCann LA, Mather LE and Boyle FM: Enhancement of cisplatin
efficacy by thalidomide in a 9L rat gliosarcoma model. J
Neuroancol. 85:181–189. 2007. View Article : Google Scholar
|
|
67
|
Mihara M, Hashizume M, Yoshida H, Suzuki M
and Shiina M: IL-6/IL-6 receptor system and its role in
physiological and pathological conditions. Clin Sci (Lond).
122:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Heinrich PC, Behrmann I, Muller-Newen G,
Schaper F and Graeve L: Interleukin-6-type cytokine signalling
through the gp130/Jak/STAT pathway. Biochem J. 334:297–314. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Cross-Knorr S, Lu S, Perez K, Guevara S,
Brilliant K, Pisano C, Quesenberry PJ, Resnick MB and Chatterjee D:
RKIP phosphorylation and STAT3 activation is inhibited by
oxaliplatin and camptothecin and are associated with poor prognosis
in stage II colon cancer patients. BMC Cancer. 13:4632013.
View Article : Google Scholar : PubMed/NCBI
|
